Company intelligence / Profile preview

Eddington-Jingang

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Eddington-Jingang is a biotechnology joint venture established between UK-based interests and Beijing Jingang Biotech. The company is dedicated to the development of novel monoclonal antibodies for the treatment of cancer. Its lead program, EJ-001, is a humanized anti-PD-L1 antibody that has progressed into Phase 2 clinical trials for indications such as non-small cell lung cancer. The venture aims to combine international research expertise with Chinese clinical and commercial infrastructure to bring advanced immunotherapies to market.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Beijing Jingang Biotech

Beyond the preview

Go deeper on Eddington-Jingang.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eddington-Jingang.

Explore the full profile